Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ligelizumab in Japanese patients with CSU
NCT03907878Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2019
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ligelizumab in chronic spontaneous urticaria (CSU), sponsored by Novartis. Primary endpoint: Safety and Tolerability of Ligelizumab 120 mg q4w Treatment for 12 Months at 64 weeks. Started Apr 2019; status: completed.
02
Drugs
ligelizumab
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT03907878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03907878.